Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cipterbin +/- Vinorelbine in HER2+ Metastatic Breast Cancer
NCT01439191Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jul 2005
- Primary completion
- Feb 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inetetamab in breast cancer (2 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Overall Response Rate at 24 weeks. Started Jul 2005; status: completed.
02
Drugs
inetetamab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01439191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01439191.